Psoriasis

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.

RDN2150 TFA is a ZAP-70 inhibitor with an IC₅₀ of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 TFA inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 TFA can be used for psoriasis-related research.

Methotrexate (Standard) (Amethopterin (Standard); CL14377 (Standard); WR19039 (Standard)) is the analytical standard of Methotrexate (HY-14519). This product is intended for research and analytical applications. Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.

Rosin is a natural oleoresin found in coniferous trees of the genus Pinus, such as Pinus massoniana. Rosin exhibits cholesterol-lowering, anti-gastric ulcer, anti-tumor, blood glucose-lowering, and anti-macrocyte aggregation activities. Rosin inhibits TPA (HY-18739)-induced EBV-EA activation and suppresses papilloma formation in a two-stage mouse skin carcinogenesis model. WBR, a processed product of Rosin, inhibits the IL-23/IL-17 inflammatory axis and reduces Th1 and Th17 cell infiltration. Rosin is used in research on psoriasis and skin cancer.

Khasianine is a steroidal glycoalkaloid. Khasianine alleviates psoriasis-like skin inflammation by inhibiting the TNF-α/NF-κB axis. Khasianine can downregulate the RhoA pathway and exhibits potential antimetastatic activity. Khasianine upregulates the expression of TNFR I and TNFR II without inducing apoptotic effects. Khasianine can be used in studies related to psoriasis, pancreatic ductal adenocarcinoma, and liver cancer.

B3GNT2-IN-1 is a β-1,3-N-acetylglucosaminyltransferase 2 (B3GNT2) inhibitor with an IC₅₀ of 0.009 μM. B3GNT2-IN-1 is applicable to research related to rheumatoid arthritis, ankylosing spondylitis and psoriasis.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis.

(±)-Coriolic acid ((±)-13-HODE) is one of the two racemic monohydroxy fatty acids produced by non-enzymatic oxidation of linoleic acid. (±)-Coriolic acid induces TNF production in macrophages and upregulates Scavenger Receptor, thereby promoting the uptake of oxidized low-density lipoprotein. (±)-Coriolic acid induces the expression of cell adhesion molecules in endothelial cells. (±)-Coriolic acid can be used in research on psoriasis, atherosclerosis, and triple-negative breast cancer.

Lumisterol (9β,10α-Ergosterol) is a photoproduct of 7-dehydrocholesterol, present in the skin, and acts as an orally active VDR non-genomic modulator and ROR inverse agonist. Lumisterol binds to the SARS-CoV-2 Mpro substrate-binding pocket and the RdRP active site, inhibiting enzyme activity. Lumisterol induces NRF2-regulated antioxidant responses, p53 phosphorylation and nuclear translocation, and intracellular free radical scavenging. Lumisterol inhibits the proliferation of epidermal keratinocytes and melanoma cells, modulates cell cycle progression, and suppresses basal and TNFα-induced NFκB transcriptional activity. Lumisterol inhibits RORγ transcriptional activity and IL-17 production. Lumisterol is used in research on UVB-induced skin damage, melanoma, psoriasis, vitamin D deficiency, and COVID-19.

TCB-32 (Compound I-1) hydrochloride is a FGFR1 agonist with an EC₅₀ of 0.88  μM. TCB-32 hydrochloride significantly increases cell proliferation through activating FGFR1 signaling pathway as bFGF and its downstream ERK1/2 with excellent thermal stability. TCB-32 hydrochloride can replace bFGF in serum-free cell culture media. TCB-32 hydrochloride can be used for tissue repair and wound healing related diseases like psoriasis and eczema research.

Envudeucitinibum (Envudeucitinib; ESK-001) is an orally active and selective TYK2 allosteric inhibitor with an IC₅₀ range of 104-149 nM. Envudeucitinibum blocks JH1 catalytic activity by specifically binding to the JH2 domain of TYK2, thereby inhibiting downstream signaling pathways. Envudeucitinibum is used for research on plaque psoriasis, systemic lupus erythematosus, and other immune-mediated diseases.

Methotrexate-d₃ is the deuterated-labeled Methotrexate (HY-14519). Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.

Morcamilast (ME3183) is a potent, orally active, selective phosphodiesterase 4 (PDE4) inhibitor, with IC₅₀ values of 1.28 nM, 2.33 nM and 1.63 nM against human PDE4A1A, PDE4B1 and PDE4D2, respectively. Morcamilast inhibits the production of TNF-α, IL-12/23p40, IL-23, IL-17A, IL-4, IL-5 and IL-13 in human PBMCs and T cells, and alleviates chronic Oxazolone (HY-126360)-induced dermatitis, Substance P (HY-P0201)-induced pruritus, Imiquimod (HY-B0180)-induced psoriasis-like dermatitis and LPS (HY-D1056)-induced arthritis. Morcamilast is used for the research of psoriasis, atopic dermatitis, psoriatic arthritis and other inflammatory and immune-related diseases.

Psora-4 (5-(4-Phenylbutoxy) psoralen) is a selective K_v1.3 blocker (K_d = 3 nM). Psora-4 increases mitochondrial ROS production, activates stress response genes including daf-16 targets and heat shock proteins, reduces triglyceride accumulation, extends lifespan and healthspan in C. elegans, and increases resistance to Paraquat-induced oxidative stress. Psora-4 can be used for research on psoriasis and obesity.

Diflorasone is a potent topical anti-inflammatory Corticosteroid. Diflorasone induces vasoconstriction when applied topically. Diflorasone can be used in research related to psoriasis, atopic dermatitis/neurodermatitis.

Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis.

Licoisoflavone B is an orally active flavonoid found in licorice. Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17-mediated inflammation. Licoisoflavone B inhiibits superoxide anion generation and superoxide anion-induced lipid peroxidation. Licoisoflavone B binds tightly to Lassa virus nucleoprotein and can be used as a nucleoprotein antagonist of Lassa virus. Licoisoflavone B exhibits anti-mutagenic activity
against carcinogenic mutagen, by preventing DNA damage. Licoisoflavone B can be used for the research of psoriasis, Lassa fever, inflammation and cancer.

12(R)-HETE is a CYP-dependent arachidonic acid metabolite that acts as a proinflammatory lipid mediator. 12 (R)-HETE widely exists in various tissues including the eye, skin and liver. In the cornea, 12(R)-HETE is metabolized via pathways such as β-oxidation into the precursor of 12(R)-HETrE. Without direct receptor binding, 12(R)-HETE indirectly activates AHR-mediated target gene transcription, while inhibiting the enzymatic activity of Na+,K+-ATPase and the intracellular calcium elevation induced by TP agonists. 12(R)-HETE also possesses multiple physiological effects such as chemotaxis, proangiogenesis, vasodilation, natriuresis, diuresis and intraocular pressure reduction, and can be widely used in studies related to psoriasis, inflammatory skin diseases and ocular inflammation.

Gomisin M2 ((+)-Gomisin M2) is a lignan isolated from the fruits of Schisandra chinensis with oral availability. Gomisin M2 inhibits STAT1 phosphorylation as well as NF-κB p65 phosphorylation and nuclear translocation. Gomisin M2 reduces inflammatory cell infiltration, cytokine and chemokine expression, and serum IgE and IgG_2a levels. Gomisin M2 inhibits MAPK phosphorylation, IκBα degradation, and NF-κB nuclear translocation in keratinocytes. Gomisin M2 induces apoptosis, mitochondrial membrane potential disruption, and cytochrome c release, and inhibits DNA synthesis and mammosphere formation through downregulation of Wnt/β-catenin. Gomisin M2 can be used for research on atopic dermatitis, psoriasis, breast cancer, liver injury, and multidrug-resistant mammary adenocarcinoma.

Isosorbide di-(methyl fumarate) (IDMF), topical DMF (HY-17363) derivative, is an NRF2/ARE pathway activator. Isosorbide di-(methyl fumarate) downregulates ANCR targets, modulates epithelial differentiation, represses proinflammatory cytokine genes, IL-17A- and TNF-induced keratinocyte genes, psoriatic skin lesion-specific genes, and immune response genes. Isosorbide di-(methyl fumarate) stimulates oxidative stress response gene transcription, reduces erythema and scaling in Imiquimod (HY-B0180)-induced psoriasiform lesions. Isosorbide di-(methyl fumarate) exhibits no genotoxicity or radiation sensitivity in skin fibroblasts, is nonirritating and nonsensitizing in rodent models. Isosorbide di-(methyl fumarate) can be used for the research of psoriasis vulgaris.